Inherited genetic variant influences response to leukemia treatment for some children
(St. Jude Children's Research Hospital) St. Jude researchers showed that an inherited variant of the GATA3 gene is tied to minimal residual disease levels and response to therapy for acute lymphoblastic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2020 Category: Cancer & Oncology Source Type: news

Late Morbidity, Mortality Down for Survivors of Childhood ALL
THURSDAY, Aug. 20, 2020 -- Contemporary survivors of childhood acute lymphoblastic leukemia (ALL) have reduced late morbidity and mortality, according to a study published online July 24 in the Journal of Clinical Oncology. Stephanie B. Dixon,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 21, 2020 Category: Pharmaceuticals Source Type: news

Understanding 'Chemo Brain' in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk
August 11, 2020—(BRONX, NY)—Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers atAlbert Einstein College of Medicine,Children’s Hospital at Montefiore (CHAM), andRutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop p...
Source: Einstein News - August 11, 2020 Category: Universities & Medical Training Source Type: news

Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
FRIDAY, July 31, 2020 -- Survivors of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) may experience late effects, with a high incidence of subsequent endocrine disease and cardiac disease, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2020 Category: Pharmaceuticals Source Type: news

A spin-off to develop therapies for leukaemia based on CAR-T, by Josep Carreras Institute
(Josep Carreras Leukaemia Research Institute) Invivo Ventures, CDTI-Innvierte (Spanish Ministry of Industry) and the Josep Carreras Foundation have established a first round of funding of € 3,050,000. OCI will carry out three projects, the most advanced of which is a CAR-T CD1a (OCI-1) project for the treatment of cortical T-cell acute lymphoblastic leukemia (coT-ALL), a subtype of leukaemia that mainly affects children and which has a poor prognosis if patients do not respond to standard treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2020 Category: International Medicine & Public Health Source Type: news

What Are Some Pediatric Oncological Emergencies?
Discussion Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Good Diet May Cut Toxicity Risk in Treatment of Pediatric ALL
TUESDAY, June 30, 2020 -- Diets high in antioxidant-rich foods may cut the risk of developing bacterial infections or mucositis during the first phase of acute lymphoblastic leukemia (ALL) treatment in pediatric patients, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2020 Category: Pharmaceuticals Source Type: news

Treating leukaemia more effectively
(Goethe University Frankfurt) Acute lymphoblastic leukaemia (ALL) is the most common kind of cancer in children. T-ALL, a subtype that resembles T-lymphocytes, can be treated successfully with the drug nelarabine. The drug has not been successful, however, with B-ALL, a subtype resembling B-lymphocytes. This has puzzled oncologists sinced the 1980's. Now, an international research team headed by Goethe University and the University of Kent has discovered the reason: B-ALL cells contain the enzyme SAMHD1, which deactivates the drug. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 24, 2020 Category: Biology Source Type: news

What if child maltreatment were childhood leukemia? Lessons from the halls of the hospital - Babcock P.
This article examines lessons that can be applied to prevention, research, training, and clinical treatment in child welfare from analogous experiences in combatting childhood acute lymphoblastic leukemia (ALL). Since the 1960s, childhood cancer researcher... (Source: SafetyLit)
Source: SafetyLit - June 9, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL
A universal chimeric antigen receptor (CAR) T-cell therapy produced responses in adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) in initial findings from an ongoing study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo
A new analysis of 8300 patients with ALL undergoing chemotherapy revealed that secondary ALL is common, and the prolonged long-term survival rate is 30% to 50%. Women had a lower risk of death than men.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

First-in-Human Trial of TruUCAR GC027 in Relapsed/Refractory T-Cell ALL Announced
The first-in-human clinical trial for TruUCAR GC027 in relapsed or refractory T-cell acute lymphoblastic leukemia was announced by Gracell Biotechnologies. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Discovered the physiological mechanisms underlying the most common pediatric Leukemia
(Josep Carreras Leukaemia Research Institute) Researchers from the Josep Carreras Leukaemia Research Institute unveil the mechanisms that lead to hyperdiploid Acute Lymphoblastic Leukemia, Hyper D-ALL, the most common pediatric B-cell Leukaemia. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2020 Category: Biology Source Type: news

Study reveals properties of cells fated to relapse in acute lymphoblastic leukemia
(St. Jude Children's Research Hospital) Researchers have found that genetically defined subpopulations of leukemia cells present at diagnosis have distinct characteristics that lead to relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 3, 2020 Category: Cancer & Oncology Source Type: news

Isolated Extramedullary Relapse in Acute Lymphoblastic Leukemia: What Can We Do Before and After Transplant?
The case of a 43-year-old male with a history of B-cell acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Santiago Riviello-Goya, MD, Aldo A. Acosta-Medina, MD, Sergio I. Inclan-Alarcon, MD, Sofia Garcia-Miranda, MD, Christianne Bourlon, MD, MHSc Source Type: news

Joseph Wynne, MD, Discusses Developments in the Field of Acute Lymphoblastic Leukemia
The ALL expert spoke about new research in the field and how it has changed the landscape for this disease. (Source: CancerNetwork)
Source: CancerNetwork - January 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Dasatinib Tops Imatinib for Ph + Acute Lymphoblastic Leukemia
Four - year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 21, 2020 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Pharmacy, Journal, Source Type: news

Dasatinib Tops Imatinib for Ph & #43; Acute Lymphoblastic Leukemia
TUESDAY, Jan. 21, 2020 -- Dasatinib is associated with improved survival for pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to a study published online Jan. 16 in JAMA Oncology. Shuhong Shen,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2020 Category: Pharmaceuticals Source Type: news

Defining the Landscape of Mutations Present in Pediatric Acute Lymphoblastic Leukemia
This research has the potential to aid in the development of new strategies for early detection of relapse in pediatric patients with ALL, and the development of treatments to counter clinical occurrence. (Source: CancerNetwork)
Source: CancerNetwork - January 20, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Children treated for acute lymphoblastic leukemia may grow up to have heart problems, study finds
(Natural News) Acute lymphoblastic leukemia (ALL) is a type of cancer that affects the blood and bone marrow. It is the most common type of cancer developed by children. Although ALL is known to progress quickly, advances in modern medicine have increased the survival rate of children with this disease. However, a recent study by researchers... (Source: NaturalNews.com)
Source: NaturalNews.com - December 24, 2019 Category: Consumer Health News Source Type: news

Acute leukemia patients treated with common therapy have increased risk for heart failure
(University of Pennsylvania School of Medicine) Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heightened risk of heart failure -- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine. To help identify a patient's risk for heart failure following the treatment, researchers developed a risk score (0 to 21) based on clinical and echographic variables. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2019 Category: Cancer & Oncology Source Type: news

Immunotherapy drug improves outcomes for some children with relapsed leukemia
Blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 10, 2019 Category: American Health Source Type: news

Immunotherapy drug improves outcomes for some children with relapsed leukemia
(NIH/National Cancer Institute) New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed. Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual disease, and were more likely to proceed to a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news

New approach to treating incurable leukemia in children discovered
(University of Zurich) Acute lymphoblastic leukemia is the most common form of cancer affecting children in Switzerland and, unfortunately, is often incurable. Researchers from the University of Zurich and the University Children's Hospital Zurich have now found a way to stop the driving force behind this type of leukemia at a molecular level and develop a targeted therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2019 Category: Cancer & Oncology Source Type: news

Prophylactic Cranial Irradiation May Not Be Needed in Children With ALL Prophylactic Cranial Irradiation May Not Be Needed in Children With ALL
In children with acute lymphoblastic leukemia (ALL) at risk for central nervous system (CNS) relapse, a higher dose of chemotherapy plus two extra doses of intrathecal therapy during early induction can obviate the need for prophylactic cranial irradiation, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Extension of the Notch intracellular domain ankyrin repeat stack by NRARP promotes feedback inhibition of Notch signaling
Canonical Notch signaling relies on regulated proteolysis of the receptor Notch to generate a nuclear effector that induces the transcription of Notch-responsive genes. In higher organisms, one Notch-responsive gene that is activated in many different cell types encodes the Notch-regulated ankyrin repeat protein (NRARP), which acts as a negative feedback regulator of Notch responses. Here, we showed that NRARP inhibited the growth of Notch-dependent T cell acute lymphoblastic leukemia (T-ALL) cell lines and bound directly to the core Notch transcriptional activation complex (NTC), requiring both the transcription factor RB...
Source: Signal Transduction Knowledge Environment - November 5, 2019 Category: Science Authors: Jarrett, S. M., Seegar, T. C. M., Andrews, M., Adelmant, G., Marto, J. A., Aster, J. C., Blacklow, S. C. Tags: STKE Research Articles Source Type: news

Exercise Intolerance May Harm Neurocognition in ALL Survivors
MONDAY, Oct. 21, 2019 -- For adult survivors of childhood acute lymphoblastic leukemia (ALL), exercise intolerance is associated with worse neurocognitive outcomes, according to a study published online Oct. 21 in Cancer. Nicholas S. Phillips, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 21, 2019 Category: Pharmaceuticals Source Type: news

Can More Exercise Improve Thinking Skills in Cancer Survivors?
MONDAY, Oct. 21, 2019 -- Boosting exercise capacity may protect the mental functioning of childhood leukemia survivors, according to a new study. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Due to their disease and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 21, 2019 Category: General Medicine Source Type: news

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Cancer sufferer, five, who has always wanted to be a tattoo artist lives out her dream
The five-year-old girl, known only as Maja, is battling acute lymphoblastic leukaemia. She visited a local tattoo parlour in Cleveland, Ohio, where she was shown all the tools. (Source: the Mail online | Health)
Source: the Mail online | Health - September 27, 2019 Category: Consumer Health News Source Type: news

Amgen announces positive results from two Phase 3 BLINCYTO ® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia
Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with (Source: World Pharma News)
Source: World Pharma News - September 25, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Micafungin As Antifungal Prophylaxis during Induction Phase of Chemotherapy in Pediatric Acute Lymphoblastic Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - September 22, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Medicare Now Covers CAR T-Cell Therapy for Approved Cancers
A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is...
Source: Asbestos and Mesothelioma News - September 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New leukaemia drug produces 'very positive results' in a trial of 'incurable' patients
Ten-year-old Austin Sweeney has acute lymphoblastic leukaemia. He took part in the Great Ormond Street Hospital trial in London. He is pictured with his father Scott, mother and sister. (Source: the Mail online | Health)
Source: the Mail online | Health - September 2, 2019 Category: Consumer Health News Source Type: news

Delays in CAR T-Cell Treatment Cost Patients, Society
Delays in CAR T-cell therapy may significantly decrease gains in survival and productivity for patients with diffuse large B-cell lymphoma and pediatric  acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - August 30, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Overweight, Obesity May Up Early Mortality Risk in Pediatric ALL
MONDAY, Aug. 5, 2019 -- For Mexican children with acute lymphoblastic leukemia (ALL), overweight and obesity are predictors of early mortality, according to a study published online July 18 in BMC Cancer. Juan Carlos N úñez-Enríquez, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 5, 2019 Category: Pharmaceuticals Source Type: news

Acute Leukemia | Medscape Acute Leukemia | Medscape
Acute forms of leukemia include acute myeloid leukemia and acute lymphoblastic leukemia, also known as lymphoblastic lymphoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 3, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news

Miraculous children's therapy that could finally save adults with cancer
Scott Davies, a driving instructor from Nottingham, had a form of blood cancer - acute lymphoblastic leukaemia, which affects 650 UK adults and children each year. (Source: the Mail online | Health)
Source: the Mail online | Health - July 2, 2019 Category: Consumer Health News Source Type: news

Anesthesia Tied to Neurocognitive Impairment in Childhood ALL Survivors
TUESDAY, June 25, 2019 -- Multiple exposures to general anesthesia may be associated with neurocognitive impairment and brain imaging abnormalities in long-term survivors of childhood acute lymphoblastic leukemia (ALL), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 25, 2019 Category: Pharmaceuticals Source Type: news

Virginia family of eight stuck in Colorado after 16-year-old son's 'mono' turned out to be leukemia 
Marshall Thomas, 16, of Suffolk, Virginia, was diagnosed with B-cell acute lymphoblastic leukemia on Saturday in Colorado after doctors previously believe he had mononucleosis. (Source: the Mail online | Health)
Source: the Mail online | Health - June 19, 2019 Category: Consumer Health News Source Type: news

Amgen Announces BLINCYTO ® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia More Than Half of Patients who Achieved an MRD-Negative Complete Response Still Alive at Five Years Only CD19-Targeted Immuno-oncology Therapy With Five-Year Survival Data THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive acute lympho...
Source: Amgen News Release - June 16, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New research paves the way for safer leukemia treatments
(Children's Cancer Institute Australia) Researchers have discovered a new, safer way to treat a type of childhood leukaemia: T-cell acute lymphoblastic leukemia (T-ALL). Published in Science Translational Medicine, this joint research by Children's Cancer Institute (Australia), VIB-KU Leuven and UK Dementia Research Institute, is an important breakthrough in the treatment of T-ALL. This involves drugs which inhibit the enzyme 'gamma-secretase'. Previously, these inhibitors were unsuitable for treating children because of their toxicity. This research may be the solution. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2019 Category: Cancer & Oncology Source Type: news

Recovery twice as hard for survivors of childhood acute lymphoblastic leukemia
(University of Montreal) The cardiorespiratory fitness of survivors of childhood acute lymphoblastic leukemia is 22% worse than that general Canadian population,and genetics might play a role, an UdeM researcher finds. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2019 Category: Cancer & Oncology Source Type: news

SERENA LIPSCOMB got her cancer all-clear aged eight... but the physical and mental toll never ends
SERENA LIPSCOMB, now 23, was living in Essex with her mother Melanie and father Ian when she was diagnosed with acute lymphoblastic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - May 18, 2019 Category: Consumer Health News Source Type: news

Florida's medical police state abducts healthy three-year-old from parents for refusing unnecessary chemotherapy treatments
(Natural News) Another American family is facing a barrage of persecution from the corrupt medical establishment for refusing chemotherapy treatments for their three-year-old son, Noah – who doesn’t even have cancer, by the way. Young Noah had previously been diagnosed with acute lymphoblastic leukemia at Johns Hopkins All Children’s Hospital in Tampa, Florida, where his... (Source: NaturalNews.com)
Source: NaturalNews.com - May 6, 2019 Category: Consumer Health News Source Type: news

First major study of proteins in patients with acute lymphoblastic leukaemia
(Lund University) The most common form of childhood cancer is acute lymphoblastic leukaemia (ALL). Researchers at Lund University in Sweden, in cooperation with Karolinska Institutet, SciLifeLab and the University of Cambridge, have now carried out the most extensive analysis to date of ALL at the protein level, by studying the activity in over 8 000 genes and proteins. The results show aberrant folding in the DNA string, which in turn affects the genes' activity. The study was recently published in Nature Communications. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news

Model was in shape of his life when his sore throat turned out to be leukemia
William Yank, 21, from Indianapolis, Indiana, was diagnosed with acute lymphoblastic leukemia in June 2018. It was a shock to the college student, who was a model that worked out almost everyday. (Source: the Mail online | Health)
Source: the Mail online | Health - April 24, 2019 Category: Consumer Health News Source Type: news

In the Loop: Gabe's bell to 'honor the fighting, remember the resting, and party on with the survivors'
Gabe Carranza walked into the lobby on the 16th floor of the Mayo Building. It was a walk he'd made more times than he could count over the past three years and 70 days. But this walk was different. It marked the end of Gabe's treatment for?acute lymphoblastic leukemia. The lobby was filled with family, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 2, 2019 Category: Databases & Libraries Source Type: news

Five-year-old who won the nation’s heart in his battle against leukaemia has found a stem-cell donor
Oscar Saxelby-Lee, of St John's, Worcester, was diagnosed with the aggressive blood cancer acute lymphoblastic leukaemia on December 28 last year after his parents noticed bruising. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2019 Category: Consumer Health News Source Type: news